Methylergonovine — Discount Pricing

Other medications in Women's Health

• Mifepristone
• Misoprostol Cervical
• Nifedipine (Tocolytic)
• Norethindrone-Ethinyl Estradiol
• Oxytocin
• Progesterone Vaginal
• Relugolix
• Terbutaline

About Methylergonovine

Methylergonovine is a crucial medication often prescribed to new mothers to help manage and prevent excessive bleeding after childbirth. Understanding its role in postpartum care and how to access it affordably is important. TheDrugClub is dedicated to helping members like you find cost-effective solutions for essential prescriptions, including methylergonovine.

Methylergonovine is primarily used to prevent and treat postpartum hemorrhage (excessive bleeding after childbirth) and uterine atony (when the uterus fails to contract sufficiently after delivery). It's also sometimes used following a miscarriage or abortion to ensure the uterus expels all contents and contracts properly. Its role is vital in preventing serious complications that can arise from uncontrolled bleeding, making it a critical component of maternal care.

As an ergot alkaloid, methylergonovine works by directly stimulating the smooth muscle of the uterus. This causes strong, sustained uterine contractions, which compress blood vessels in the uterine wall. By constricting these vessels, the medication effectively reduces blood loss and helps the uterus return to its normal size and

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Methylergonovine is approved for (FDA label)

Following delivery of the placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus. For control of uterine hemorrhage in the second stage of labor following delivery of the anterior shoulder.

Source: Read the full FDA label on DailyMed. Label effective date: June 12, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Methylergonovine (FDA label)

Clinical trials experience Common Adverse Reactions The most common adverse reaction is hypertension associated in several cases with seizure and/or headache. Hypotension has also been reported. Abdominal pain (caused by uterine contractions), nausea and vomiting have occurred occasionally. Rare Adverse Reactions Rarely observed reactions have included: acute myocardial infarction, transient chest pains, vasoconstriction, vasospasm, coronary arterial spasm, bradycardia, tachycardia, dyspnea, hematuria, thrombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diarrhea, diaphoresis, palpitation, rash, and foul taste. There have been rare isolated reports of anaphylaxis, without a proven causal relationship to the drug product. Postmarketing Experience The following adverse drug reactions have been derived from post-marketing experience with methylergonovine maleate via spontaneous case reports.

Source: FDA prescribing information (DailyMed). Set ID: a7ec8dfe-9b58-4363-a709-c1b72ee67855. SPL document ID: 5c53f000-01eb-4042-bdb8-e569609413bf. Label effective date: June 12, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Methylergonovine (FDA label)

Hypertension; toxemia; pregnancy; and hypersensitivity.

Source: FDA prescribing information (DailyMed). Set ID: a7ec8dfe-9b58-4363-a709-c1b72ee67855. SPL document ID: 5c53f000-01eb-4042-bdb8-e569609413bf. Label effective date: June 12, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Methylergonovine (FDA label)

CYP 3A4 Inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the co-administration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. Examples of some of the strong CYP 3A4 inhibitors include saquinavir grapefruit juice, nefazodone, macrolide antibiotics (e.g., troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Moderate inhibitors include fluconazole, fluvoxamine and clotrimazole. Weak CYP 3A4 inhibitors should be administered with caution. Weak inhibitors include chlorzoxazone, cilostazol, and ranitidine.

Source: FDA prescribing information (DailyMed). Set ID: a7ec8dfe-9b58-4363-a709-c1b72ee67855. SPL document ID: 5c53f000-01eb-4042-bdb8-e569609413bf. Label effective date: June 12, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.